Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8808397 | 0.84 | MAPT (0.60) | MAPTMEN1KMT2APIN1CNR1 | |
| SCHEMBL9388459 | 0.83 | MEN1 (0.58) | MAPTMEN1KMT2ACYP19A1CYP11B1 | |
| SCHEMBL2191697 | 0.82 | MAPT (0.65) | MAPTMEN1KMT2ACNR1ACHE | |
| SCHEMBL29433280 | 0.82 | MAPT (0.65) | MAPTMEN1KMT2ACNR1ACHE | |
| SCHEMBL31440585 | 0.81 | MAPT (0.53) | MAPTMEN1KMT2ACNR1ACHE | |
| SCHEMBL2419677 | 0.81 | MAPT (0.50) | MAPTMEN1KMT2ACNR1ACHE | |
| SCHEMBL10599878 | 0.80 | CYP19A1 (0.52) | MAPTKMT2ACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5262050 | 0.80 | PIN1 (0.56) | MAPTMEN1KMT2APIN1CNR1 | |
| SCHEMBL31442728 | 0.79 | MEN1 (0.61) | MAPTMEN1KMT2ACNR1ACHE | |
| SCHEMBL21071296 | 0.79 | HTR1A (0.55) | MAPTMEN1KMT2ACYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
| US-8236984-B2 | Compound and use thereof in the treatment of amyloidosis | PENTRAXIN THERAPEUTICS LTD. (GB) | 2012-08-07 | — | — | US | disclosed |
| US-8236984-B2 | Compound and use thereof in the treatment of amyloidosis | PENTRAXIN THERAPEUTICS LTD. (GB) | 2012-08-07 | — | — | US | disclosed |
| US-20100249233-A1 | COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-20100249233-A1 | COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| EP-2203167-A1 | COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS | Pentraxin Therapeutics Limited (GB) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009040405-A1 | COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249233-A1 | COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS | TTR, APP, C1QBP | MAPT 35/4885MEN1 539/4885KMT2A 3465/4885 |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | MAPT 543/4885MEN1 2876/4885KMT2A 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.